Roth Capital initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $31 price target The company’s LB-102, a Phase 3-ready schizophrenia agent, had “robust” Phase 2 data and its strong cash position set the stage for a Phase 3 initiation in Q1, the analyst tells investors in a research note. Roth says LB’s has a “significantly de-risked approach” to treating schizophrenia.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX:
- LB Pharmaceuticals appoints Ellen Rose as SVP, corporate affairs
- These 3 Biotech Stocks Can Triple from Current Levels, Say Five-Star Analysts – 12/19/2025
- LB Pharmaceuticals management to meet with Piper Sandler
- LB Pharmaceuticals price target raised to $35 from $27 at Stifel
- LB Pharmaceuticals added to Russell 2000, Russell 3000 indices